🚀 VC round data is live in beta, check it out!
Jamjoom Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jamjoom Pharma and similar public comparables like D&D Pharmatech, Cosmo Pharmaceuticals, BioKangtai, Wockhardt and more.
Jamjoom Pharma Overview
About Jamjoom Pharma
Jamjoom Pharmaceuticals Factory Co is engaged in the development, manufacture, and marketing of a wide range of high-quality branded generic pharmaceuticals, including pharmaceuticals and consumer health products, with the majority of revenue coming from pharmaceutical sales. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
Founded
1994
HQ
Employees
1.1K
Website
Sectors
Financials (LTM)
EV
$2B
Jamjoom Pharma Financials
Jamjoom Pharma reported last 12-month revenue of $413M and EBITDA of $138M.
In the same LTM period, Jamjoom Pharma generated $258M in gross profit, $138M in EBITDA, and $126M in net income.
Revenue (LTM)
Jamjoom Pharma P&L
In the most recent fiscal year, Jamjoom Pharma reported revenue of $352M and EBITDA of $112M.
Jamjoom Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $413M | XXX | $352M | XXX | XXX | XXX |
| Gross Profit | $258M | XXX | $219M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $138M | XXX | $112M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $126M | XXX | $95M | XXX | XXX | XXX |
| Net Margin | 31% | XXX | 27% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jamjoom Pharma Stock Performance
Jamjoom Pharma has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Jamjoom Pharma's stock price is $34.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $1.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJamjoom Pharma Valuation Multiples
Jamjoom Pharma trades at 5.8x EV/Revenue multiple, and 17.4x EV/EBITDA.
EV / Revenue (LTM)
Jamjoom Pharma Financial Valuation Multiples
As of March 16, 2026, Jamjoom Pharma has market cap of $2B and EV of $2B.
Equity research analysts estimate Jamjoom Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jamjoom Pharma has a P/E ratio of 19.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 17.4x | XXX | 21.4x | XXX | XXX | XXX |
| EV/EBIT | 19.0x | XXX | 22.2x | XXX | XXX | XXX |
| EV/Gross Profit | 9.3x | XXX | 11.0x | XXX | XXX | XXX |
| P/E | 19.4x | XXX | 25.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 43.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jamjoom Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jamjoom Pharma Margins & Growth Rates
Jamjoom Pharma's revenue in the last 12 month grew by 16%.
Jamjoom Pharma's revenue per employee in the last FY averaged $0.4M.
Jamjoom Pharma's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jamjoom Pharma's rule of X is 73% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Jamjoom Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 73% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 24% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jamjoom Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| D&D Pharmatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Cosmo Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| BioKangtai | XXX | XXX | XXX | XXX | XXX | XXX |
| Wockhardt | XXX | XXX | XXX | XXX | XXX | XXX |
| Dermapharm Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jamjoom Pharma M&A Activity
Jamjoom Pharma acquired XXX companies to date.
Last acquisition by Jamjoom Pharma was on XXXXXXXX, XXXXX. Jamjoom Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jamjoom Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJamjoom Pharma Investment Activity
Jamjoom Pharma invested in XXX companies to date.
Jamjoom Pharma made its latest investment on XXXXXXXX, XXXXX. Jamjoom Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jamjoom Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jamjoom Pharma
| When was Jamjoom Pharma founded? | Jamjoom Pharma was founded in 1994. |
| Where is Jamjoom Pharma headquartered? | Jamjoom Pharma is headquartered in Saudi Arabia. |
| How many employees does Jamjoom Pharma have? | As of today, Jamjoom Pharma has over 1K employees. |
| Is Jamjoom Pharma publicly listed? | Yes, Jamjoom Pharma is a public company listed on Tadawul. |
| What is the stock symbol of Jamjoom Pharma? | Jamjoom Pharma trades under 4015 ticker. |
| When did Jamjoom Pharma go public? | Jamjoom Pharma went public in 2023. |
| Who are competitors of Jamjoom Pharma? | Jamjoom Pharma main competitors are D&D Pharmatech, Cosmo Pharmaceuticals, BioKangtai, Wockhardt. |
| What is the current market cap of Jamjoom Pharma? | Jamjoom Pharma's current market cap is $2B. |
| What is the current revenue of Jamjoom Pharma? | Jamjoom Pharma's last 12 months revenue is $413M. |
| What is the current revenue growth of Jamjoom Pharma? | Jamjoom Pharma revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Jamjoom Pharma? | Current revenue multiple of Jamjoom Pharma is 5.8x. |
| Is Jamjoom Pharma profitable? | Yes, Jamjoom Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jamjoom Pharma? | Jamjoom Pharma's last 12 months EBITDA is $138M. |
| What is Jamjoom Pharma's EBITDA margin? | Jamjoom Pharma's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Jamjoom Pharma? | Current EBITDA multiple of Jamjoom Pharma is 17.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.